المؤلفون: Stuart Sherman, Maria Hofbauer, Suzette E. Schmidt, Mark A. Gromski, Akbar K. Waljee, Paul R. Tarnasky, Douglas K. Pleskow, Alejandro L Suarez, Richard S. Kwon, Marilyn E. Miller, Seena Arol, Nalini M. Guda, Lee McHenry, Grace H. Elta, B. Joseph Elmunzer, Sheryl Korsnes, Evan L. Fogel, Ihab I. El Hajj, Rebecca L. Spitzer, Gregory A. Cote, Peter D.R. Higgins, Jeffrey J. Easler, James L. Watkins, James M. Scheiman, Glen A. Lehman

المصدر: The Lancet Gastroenterology & Hepatology. 5:132-141

مصطلحات موضوعية: Male, medicine.medical_specialty, Indomethacin, Placebo, Severity of Illness Index, law.invention, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, Indometacin, Administration, Rectal, Risk Factors, law, Internal medicine, Humans, Medicine, Adverse effect, Retrospective Studies, Cholangiopancreatography, Endoscopic Retrograde, Endoscopic retrograde cholangiopancreatography, Dose-Response Relationship, Drug, Hepatology, medicine.diagnostic_test, business.industry, Incidence, Anti-Inflammatory Agents, Non-Steroidal, Gastroenterology, Retrospective cohort study, Middle Aged, medicine.disease, United States, Regimen, Treatment Outcome, Pancreatitis, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3995398345190382e957692d5c38bc7a
https://doi.org/10.1016/s2468-1253(19)30337-1